Fulvestrant is a selective estrogen receptor degrader used in the treatment of hormone-receptor positive and HER2- advanced breast cancer in post-menopausal woman who have not previously been treated with endocrine therapy. The gene discussed is NR4A1; the disease is breast carcinoma.